Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults.

Publication date: Feb 01, 2024

The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0. 31 [95% confidence interval {CI}, .22-. 42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: -2. 70 [95% CI, -1. 68 to -3. 73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0. 07). Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.

Open Access PDF

Concepts Keywords
Coronavirus community-based
October COVID-19
Postinfection long COVID
Severe SARS-CoV-2
Vaccinated vaccine

Semantics

Type Source Name
disease MESH Long COVID
disease IDO symptom
disease VO vaccinated
disease VO unvaccinated
disease VO vaccination
disease MESH infection
disease MESH sequelae
disease MESH coronavirus disease 2019
disease VO USA
disease VO vaccine
disease MESH Infectious Diseases
drug DRUGBANK Stavudine
disease VO population
drug DRUGBANK Coenzyme M
disease IDO history
disease IDO blood
drug DRUGBANK Etoperidone
disease VO immunization
disease IDO acute infection
disease MESH sore throat
disease MESH cognitive dysfunction
disease MESH breakthrough infections
disease VO time
disease VO nose
disease MESH chronic fatigue syndrome
disease MESH postural orthostatic tachycardia syndrome
drug DRUGBANK Ilex paraguariensis leaf
disease VO storage
disease MESH Allergy
disease MESH Influenza
disease VO Respiratory syncytial virus vaccine
disease VO effective
disease VO Pal
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO pathogen

Original Article

(Visited 1 times, 1 visits today)